Practical Guidance for Clinical Microbiology Laboratories: Updated guidance for processing respiratory tract samples from people with cystic fibrosis
Clinical Microbiology Reviews · 12.09.2024 · 37 (3)
DOI: 10.1128/cmr.00215-21 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Microbiology Reviews, erschienen am 12.09.2024. Verfasst von Lisa Saiman und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Columbia University Irving Medical Center, New York, New York, USA. Hauptthemen laut MEDLINE: Cystic Fibrosis, Respiratory Tract Infections, Specimen Handling. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 226 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
This guidance presents recommendations for clinical microbiology laboratories for processing respiratory samples from people with cystic fibrosis (pwCF). Appropriate processing of respiratory samples is crucial to detect bacterial and fungal pathogens, guide treatment, monitor the epidemiology of cystic fibrosis (CF) pathogens, and assess therapeutic interventions. Thanks to CF transmembrane conductance regulator modulator therapy, the health of pwCF has improved, but as a result, fewer pwCF spontaneously expectorate sputum. Thus, the collection of sputum samples has decreased, while the collection of other types of respiratory samples such as oropharyngeal and bronchoalveolar lavage samples has increased. To optimize the detection of microorganisms, including Pseudomonas aeruginosa , Staphylococcus aureus , Haemophilus influenzae , and Burkholderia cepacia complex; other less common non-lactose fermenting Gram-negative bacilli, e.g., Stenotrophomonas maltophilia , Inquilinus , Achromobacter , Ralstonia , and Pandoraea species; and yeasts and filamentous fungi, non-selective and selective culture media are recommended for all types of respiratory samples, including samples obtained from pwCF after lung transplantation. There are no consensus recommendations for laboratory practices to detect, characterize, and report small colony variants (SCVs) of S. aureus , although studies are ongoing to address the potential clinical impact of SCVs. Accurate identification of less common Gram-negative bacilli, e.g., S. maltophilia , Inquilinus , Achromobacter , Ralstonia , and Pandoraea species, as well as yeasts and filamentous fungi, is recommended to understand their epidemiology and clinical importance in pwCF. However, conventional biochemical tests and automated platforms may not accurately identify CF pathogens. MALDI-TOF MS provides excellent genus-level identification, but databases may lack representation of CF pathogens to the species-level. Thus, DNA sequence analysis should be routinely available to laboratories for selected clinical circumstances. Antimicrobial susceptibility testing (AST) is not recommended for every routine surveillance culture obtained from pwCF, although selective AST may be helpful, e.g., for unusual pathogens or exacerbations unresponsive to initial therapy. While this guidance reflects current care paradigms for pwCF, recommendations will continue to evolve as CF research expands the evidence base for laboratory practices.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatrics, Columbia University Irving Medical Center, New York, New York, USA.
- Department of Infection Prevention and Control, NewYork-Presbyterian Hospital, New York, New York, USA.
- Division of Infectious Diseases, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
- Department of Pediatrics, University of Michigan Medical School, Ann Arbor, Michigan, USA.
- Department of Pediatrics, University of Washington, Seattle, Washington, USA.
- Department of Microbiology, University of Washington, Seattle, Washington, USA.
ORCID-Profile: Lisa Saiman, Valerie Waters, John J LiPuma, Sean X Zhang, Scott C Bell
Zitieren
APA
Saiman, L., Waters, V., LiPuma, J. J., Hoffman, L. R., Alby, K., Zhang, S. X., Yau, Y. C., Downey, D. G., Sermet-Gaudelus, I., Bouchara, J. P., Kidd, T. J., Bell, S. C., & Brown, A. W. (2024). Practical Guidance for Clinical Microbiology Laboratories: Updated guidance for processing respiratory tract samples from people with cystic fibrosis. Clinical Microbiology Reviews, 37(3). https://doi.org/10.1128/cmr.00215-21
Vancouver
Saiman L, Waters V, LiPuma JJ, Hoffman LR, Alby K, Zhang SX, et al. Practical Guidance for Clinical Microbiology Laboratories: Updated guidance for processing respiratory tract samples from people with cystic fibrosis. Clinical Microbiology Reviews. 2024;37(3). doi:10.1128/cmr.00215-21
BibTeX
@article{Saiman2024,
author = {Saiman, Lisa and Waters, Valerie and LiPuma, John J and Hoffman, Lucas R and Alby, Kevin and Zhang, Sean X and Yau, Yvonne C and Downey, Damian G and Sermet-Gaudelus, Isabelle and Bouchara, Jean-Philippe and Kidd, Timothy J and Bell, Scott C and Brown, A Whitney},
title = {Practical Guidance for Clinical Microbiology Laboratories: Updated guidance for processing respiratory tract samples from people with cystic fibrosis},
journal = {Clinical Microbiology Reviews},
year = {2024},
volume = {37},
number = {3},
doi = {10.1128/cmr.00215-21}
}
EUVIMED